A clinical trial conducted in Sweden has found that an element in human blood, fibrinogen, is likely more vital to the blood’s clotting ability in connection with heart surgery than previously considered. If the patients also receive a dose of fibrinogen prior to the procedure, this reduces the risk of hemorrhage during and after surgery. These results may open the door to new strategies in reducing bleeding complications in cardiac surgery.